H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on CGTX stock, giving a Buy rating on November 21.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Cognition Therapeutics’ promising developments with their drug candidate, zervimesine. The company has successfully completed enrollment for their expanded access program in dementia with Lewy bodies (DLB), indicating strong interest from both patients and physicians. This milestone, achieved in a short time frame, highlights the potential impact of zervimesine in addressing unmet needs in DLB, where no approved treatments currently exist.
Additionally, Cognition Therapeutics is making significant progress in regulatory discussions, with a Type C meeting scheduled with the FDA to discuss the pivotal development pathway for zervimesine in DLB. The drug has already demonstrated meaningful clinical benefits in previous trials, including slowing cognitive decline and reducing caregiver distress. Furthermore, the company is advancing its Phase 3 program for Alzheimer’s disease, with FDA alignment on trial design, which further supports the potential of zervimesine as a valuable treatment option. These developments collectively underpin Selvaraju’s confidence in the company’s prospects, justifying the Buy rating and a 12-month price target of $3.
In another report released on November 21, B. Riley Securities also maintained a Buy rating on the stock with a $3.00 price target.